Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?

•IgM oligoclonal bands against lipids negatively impact multiple sclerosis prognosis.•81.9% of the patients included had IgM oligoclonal bands against lipids.•In our study, IgM OCBs were not associated with other variables of poor prognosis.•Therefore, its routine determination in daily practice rem...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis and related disorders 2023-11, Vol.79, p.105033-105033, Article 105033
Main Authors: Ribes García, Sara, Castillo-Villalba, Jessica, Gasque Rubio, Raquel, Carratalà Boscà, Sara, Cubas-Nuñez, Laura, Alcalá, Carmen, Pérez-Miralles, Francisco Carlos, Bonaventura, Casanova Estruch
Format: Article
Language:English
Subjects:
Biomarkers
Demyelinating diseases
Multiple sclerosis
Myelin lipids
Neuroimmunology
Oligoclonal bands
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•IgM oligoclonal bands against lipids negatively impact multiple sclerosis prognosis.•81.9% of the patients included had IgM oligoclonal bands against lipids.•In our study, IgM OCBs were not associated with other variables of poor prognosis.•Therefore, its routine determination in daily practice remains controversial. various prognostic factors of multiple sclerosis have been identified, including demographic, clinical, radiological, and laboratory factors. The aim was to analyze whether the presence of IgM oligoclonal bands against lipids is associated with disease progression. an individual-based, prospective, observational study was conducted at the Neurology Department of Hospital Universitari i Politècnic la Fe. Clinical, radiological, and laboratory variables were collected. Data analysis was divided into a descriptive phase and a subsequent analytical phase. a total of 116 patients were included. 81.9% of them had IgM oligoclonal bands against lipids, with phosphatidylcholine being the predominant type. A higher proportion of patients with IgM oligoclonal bands against lipids required treatment with a disease-modifying drug, started treatment at an earlier stage, showed poorer results in functional tests, and exhibited a higher increase in lesion burden, although these differences were not statistically significant. In our study, the presence of IgM oligoclonal bands against lipids was not found to be associated with other poor prognostic variables. Graphical abstract [Display omitted]
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2023.105033